Home » Merck’s and Pfizer’s Bavencio Wins EU Approval for Urothelial Carcinoma
Merck’s and Pfizer’s Bavencio Wins EU Approval for Urothelial Carcinoma
Merck and Pfizer have won European Commission marketing authorization for Bavencio (avelumab) as a first-line maintenance treatment for adults with locally advanced or metastatic urothelial carcinoma who are progression-free after platinum-based chemotherapy.
The approval was supported by positive phase 3 results demonstrating the drug significantly improved survival in patients with advanced or metastatic bladder cancer.
Bavencio received FDA approval last June as a first-line treatment for patients with advanced urothelial carcinoma.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May